<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04292418</url>
  </required_header>
  <id_info>
    <org_study_id>PKTX</org_study_id>
    <nct_id>NCT04292418</nct_id>
  </id_info>
  <brief_title>Predictors of Rejection in Pediatric Kidney Transplantation</brief_title>
  <official_title>Predictors of Rejection in Pediatric Kidney Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Renal transplantation is the best option among the end-stage renal disease (ESRD) treatment
      alternatives, It is also relatively less expensive than dialysis. Allograft rejection is a
      major issue in kidney transplantation. Rejection is classified as acute or chronic, cellular
      or antibody-mediated.Children with kidney transplants require life-long immunosuppressive
      therapy to prevent rejection of the allograft
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The most common medication regimen in the United States includes the combination of
      corticosteroid (eg, prednisone), a calcineurin inhibitor (or CNI, most commonly tacrolimus),
      and an antimetabolite such as mycophenolate mofetil (MMF). Cyclosporine and azathioprine are
      less commonly used for maintenance immunosuppression Tacrolimus level is a main maintenance
      immunosuppressant in kidney transplantation .In the early days of posttransplant period,
      hematocrit concentrations are generally low and increase significantly as patient recovers.
      Because tacrolimus binds strongly to erythrocytes in systemic circulation, the effect of
      hematocrit on distribution of tacrolimus is important for the methods used to measure
      tacrolimus concentrations ,hematocrit correction could be a step towards improvement of
      tacrolimus dose individualization Thearputic drug monitoring of MPA has been proposed to
      optimize drug dosage avoiding potential hematologic and digestive side effects .MPA
      monitoring is generally based on the determination of the plasma MPA trough concentration
      (C0) .
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>predictors of rejection</measure>
    <time_frame>2 year</time_frame>
    <description>detect the potentially predictors of rejection in pediatric kidney transplant recipient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>measure corrected tacrolimus level and mycophenolic acid</measure>
    <time_frame>2 year</time_frame>
    <description>detect the role of corrected tacrolimus level in dose adjustment for better control of immunosuppressive therapy detect the role of neutrophil to lymphocytic ratio in prediction of kidney rejection Role of mycophenolic acid monitoring in prevention of rejection</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Rejection Acute Renal</condition>
  <arm_group>
    <arm_group_label>study group 1</arm_group_label>
    <description>(rejector group )include Paediatric living donor kidney transplant recipients (aged 4-18 years) at least 35 child recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the study group 1 measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test</description>
  </arm_group>
  <arm_group>
    <arm_group_label>study group 2</arm_group_label>
    <description>the second group (non rejector group ) include Paediatric living donor kidney transplant recipients (aged 4-18 years) recieving standard triple drug immunosuppression consisting tacrolimus an antiproliferative drug [mycophenolate mofetil (MMF) and steroids, with biopsy proven acute rejection in the studied group at least 35 child measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test in the study group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus capsule , mycophenolic acid</intervention_name>
    <description>measuring tacrolimus level by elisa test then correlated with hematocrit level measuring mycophenolic acid by elisa test for study group 1 and study group 2</description>
    <arm_group_label>study group 1</arm_group_label>
    <arm_group_label>study group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Paediatric living donor kidney transplant recipients (aged 1-18 years)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Paediatric living donor kidney transplant recipients (aged 1-18 years)

          2. patients received standard triple drug immunosuppression consisting tacrolimus an
             antiproliferative drug [mycophenolate mofetil (MMF) and steroids

          3. recipients with biopsy proven acute rejection in the studied group.

        Exclusion Criteria:

          1. patients on cyclosporine

          2. patients with active infection and dehydration

          3. Patients who received multiorgan transplantation Non cooperative patient will be
             excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aya Khalifa, master degree</last_name>
    <phone>00201016228446</phone>
    <email>dr.ayaahmedkhlifa@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Doaa Salah, MD</last_name>
    <phone>002001205551924</phone>
    <email>doaamsalah2010@yahoo.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Bulut IK, Taner S, Keskinoglu A, Sezer TO, Kabasakal C. Pediatric Kidney Transplantation in Patients With Urologic Anomalies. Transplant Proc. 2019 Sep;51(7):2257-2261. doi: 10.1016/j.transproceed.2019.01.155. Epub 2019 Aug 7.</citation>
    <PMID>31400969</PMID>
  </results_reference>
  <results_reference>
    <citation>Tamain M, Sayegh J, Lionet A, Grimbert P, Philipponnet C, Hazzan M, Augusto JF, Büchler M, Merlin E, Kosmadakis G, Tiple A, Pereira B, Garrouste C, Heng AE. Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients. Transfus Apher Sci. 2019 Aug;58(4):515-524. doi: 10.1016/j.transci.2019.06.031. Epub 2019 Jul 22.</citation>
    <PMID>31383541</PMID>
  </results_reference>
  <results_reference>
    <citation>Park WY, Paek JH, Jin K, Park SB, Han S. Long-term Clinical Significance of Tacrolimus Trough Level at the Early Period After Kidney Transplantation. Transplant Proc. 2019 Oct;51(8):2643-2647. doi: 10.1016/j.transproceed.2019.03.065. Epub 2019 Aug 30.</citation>
    <PMID>31477420</PMID>
  </results_reference>
  <results_reference>
    <citation>Akbas SH, Ozdem S, Caglar S, Tuncer M, Gurkan A, Yucetin L, Senol Y, Demirbas A, Gultekin M, Ersoy FF, Akaydin M. Effects of some hematological parameters on whole blood tacrolimus concentration measured by two immunoassay-based analytical methods. Clin Biochem. 2005 Jun;38(6):552-7.</citation>
    <PMID>15885236</PMID>
  </results_reference>
  <results_reference>
    <citation>Krischock LA, van Stralen KJ, Verrina E, Tizard EJ, Bonthuis M, Reusz G, Hussain FK, Jankauskiene A, Novljan G, Spasojević-Dimitrijeva B, Podracka L, Zaller V, Jager KJ, Schaefer F; ESPN/ERA-EDTA Registry. Anemia in children following renal transplantation-results from the ESPN/ERA-EDTA Registry. Pediatr Nephrol. 2016 Feb;31(2):325-33. doi: 10.1007/s00467-015-3201-8. Epub 2015 Sep 18.</citation>
    <PMID>26385862</PMID>
  </results_reference>
  <results_reference>
    <citation>Chinnakotla S, Verghese P, Chavers B, Rheault MN, Kirchner V, Dunn T, Kashtan C, Nevins T, Mauer M, Pruett T; MNUM Pediatric Transplant Program. Outcomes and Risk Factors for Graft Loss: Lessons Learned from 1,056 Pediatric Kidney Transplants at the University of Minnesota. J Am Coll Surg. 2017 Apr;224(4):473-486. doi: 10.1016/j.jamcollsurg.2016.12.027. Epub 2017 Feb 27.</citation>
    <PMID>28254584</PMID>
  </results_reference>
  <results_reference>
    <citation>Schijvens AM, van Hesteren FHS, Cornelissen EAM, Bootsma-Robroeks CMHHT, Brüggemann RJM, Burger DM, de Wildt SN, Schreuder MF, Ter Heine R. The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients. Pediatr Nephrol. 2019 Mar;34(3):507-515. doi: 10.1007/s00467-018-4117-x. Epub 2018 Oct 30.</citation>
    <PMID>30374607</PMID>
  </results_reference>
  <results_reference>
    <citation>Limsrichamrern S, Chanapul C, Mahawithitwong P, Sirivatanauksorn Y, Kositamongkol P, Asavakarn S, Tovikkai C, Dumronggittigule W. Correlation of Hematocrit and Tacrolimus Level in Liver Transplant Recipients. Transplant Proc. 2016 May;48(4):1176-8. doi: 10.1016/j.transproceed.2015.12.096.</citation>
    <PMID>27320581</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>February 29, 2020</last_update_submitted>
  <last_update_submitted_qc>February 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aya Khalifa</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

